Lactate dehydrogenase A (LDHA) is hormonally regulated in rodents, and increased expression of LDHA is observed during mammary gland tumorigenesis. The mechanisms of hormonal regulation of LDHA were investigated in breast cancer cells using a series of deletion and mutant reporter constructs derived from the rat LDHA gene promoter. Results of transient transfection studies showed that the -92 to -37 region of the LDHA promoter was important for basal and estrogen-induced transactivation, and mutation of the consensus CRE motif (-48/-41) within this region resulted in significant loss of basal activity and hormone-responsiveness. Gel mobility shift assays using nuclear extracts from MCF-7 cells indicated that CREB family proteins interacted with the CRE. Studies with kinase inhibitors showed that estrogen-induced activation of this CRE was dependent on protein kinase C, and these data show that LDHA is induced through a nongenomic (extranuclear) pathway of estrogen action. Estrogen activates several nongenomic pathways in MCF-7 cells, and this study investigated the effects of structurally diverse estrogenic compounds on activation of mitogen activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), protein kinase A (PKA), and calcium/calmodulin-dependent protein kinase IV (CaMKIV). Activation of kinases was determined by specific substrate phosphorylation and transactivation assays that were diagnostic for individual kinases. The compounds investigated in this study include E2, diethylstilbestrol (DES), the phytoestrogen resveratrol, and the following synthetic xenoestrogens: bisphenol-A (BPA), nonylphenol, octylphenol, endosulfan, kepone, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE), and 2',3',4',5'-tetrachloro-4-biphenylol (HO-PCB-Cl4). With theexception of resveratrol, all the compounds activated PI3K and MAPK whereas activation of PKC by the xenoestrogens was structure-dependent and resveratrol, kepone and HO-PCB-Cl4 were inactive. Only minimal estrogen/xenoestrogen-dependent activation of PKA was observed. CaMKIV was activated only by E2 and DES, and HO-PCB-Cl4 was a potent inhibitor of CaMKIV-dependent activity. These results demonstrate that activation of nongenomic pathways by estrogenic compounds in MCF-7 cells is structure-dependent.

Lactate dehydrogenase A (LDHA) is hormonally regulated in rodents, and increased expression of LDHA is observed during mammary gland tumorigenesis. The mechanisms of hormonal regulation of LDHA were investigated in breast cancer cells using a series of deletion and mutant reporter constructs derived from the rat LDHA gene promoter. Results of transient transfection studies showed that the -92 to -37 region of the LDHA promoter was important for basal and estrogen-induced transactivation, and mutation of the consensus CRE motif (-48/-41) within this region resulted in significant loss of basal activity and hormone-responsiveness. Gel mobility shift assays using nuclear extracts from MCF-7 cells indicated that CREB family proteins interacted with the CRE. Studies with kinase inhibitors showed that estrogen-induced activation of this CRE was dependent on protein kinase C, and these data show that LDHA is induced through a nongenomic (extranuclear) pathway of estrogen action. Estrogen activates several nongenomic pathways in MCF-7 cells, and this study investigated the effects of structurally diverse estrogenic compounds on activation of mitogen activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), protein kinase A (PKA), and calcium/calmodulin-dependent protein kinase IV (CaMKIV). Activation of kinases was determined by specific substrate phosphorylation and transactivation assays that were diagnostic for individual kinases. The compounds investigated in this study include E2, diethylstilbestrol (DES), the phytoestrogen resveratrol, and the following synthetic xenoestrogens: bisphenol-A (BPA), nonylphenol, octylphenol, endosulfan, kepone, 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE), and 2',3',4',5'-tetrachloro-4-biphenylol (HO-PCB-Cl4). With theexception of resveratrol, all the compounds activated PI3K and MAPK whereas activation of PKC by the xenoestrogens was structure-dependent and resveratrol, kepone and HO-PCB-Cl4 were inactive. Only minimal estrogen/xenoestrogen-dependent activation of PKA was observed. CaMKIV was activated only by E2 and DES, and HO-PCB-Cl4 was a potent inhibitor of CaMKIV-dependent activity. These results demonstrate that activation of nongenomic pathways by estrogenic compounds in MCF-7 cells is structure-dependent.

No description available.

The human colonic cell line T84, a model for studying epithelial chloride secretion and cystic fibrosis chloride channel (CFTR) function, was used to investigate the regulatory role of estrogens in transepithelial ion transport. Estrogens and other steroid hormones do not stimulate chloride secretion by themselves. However, 17 β-estradiol (17β-E2) rapidly (within seconds to minutes) potentiates carbachol- and thapsigargin-stimulated chloride secretion measured as short circuit current in voltage-clamped T84 monolayer cultures. The cholinergic agonist carbachol and the SR Ca2+ ATPase inhibitor thapsigargin stimulate chloride secretion by elevating intracellular calcium. 17α-estradiol, a stereoisomer that does not activate nuclear estrogen receptors, is equipotent with 17β-E2. Other non-estrogen steroids produce much less, if any, potentiation of calcium-stimulated chloride secretion. The estrogen receptor antagonist tamoxifen does not block 17β-E2 potentiation of calcium-stimulated chloride secretion, indicating that the classical estrogen receptors are not involved. Potentiation is greater when 17β-E2 is applied to the apical membrane than to the basolateral membrane. 17β-E2 effects on chloride secretion coincide with an increase in monolayer electrical conductance, which is consistent with activation of one or more ion channel species. Potentiation is not blocked by the chloride channel blockers DIDS and NPPB but is abolished by the PKA inhibitor H89, suggesting that 17β-E2 potentiation depends on the activity of CFTR but not other types of apical membrane chloride channels. 17β-E2 does not increase the activity of calcium-activated potassium channels in the basolateral membrane as measured in nystatin-permeabilized monolayers. 17β-E2 effects are not blocked by the MAP kinase kinase inhibitor PD 98059, or by the PKC inhibitor bisindoylmaleamide, suggesting that these signal transduction pathways are not involved. 17β-E2 potentiation requires extracellular Ca2+. Paradoxically, 17β-E2 reduces the rise in intracellular free Ca2+ levels in thapsigargin-stimulated T84 cells, as measured by fura-2 fluorescence. From my studies I conclude that 17β-E2 causes an increase in the sensitivity of T84 cells to calcium-elevating secretagogues. This effect may be due to nongenomic actions of 17β-E2 on CFTR function and/or the activity of store-operated calcium channels, which leads to a change in CFTR functional regulation.

No description available.